Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJun 2, 2021Rectiv (nitroglycerin) Ointment 0.4% For Intra-anal Use Only 30 gCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0419-2021Class IITerminatedJun 2, 2021NamzaricCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0418-2021Class IITerminatedJun 2, 2021LinzessCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0417-2021Class IITerminatedJun 2, 2021RESTASIS 0.05%30X 0.4ML OPTH PFCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0416-2021Class IITerminatedJun 2, 2021UBRELVY 100MG 10UD CPLTCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0415-2021Class IITerminatedJun 2, 2021Vaniqa (eflornithine hydrochloride) CreamCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0414-2021Class IITerminatedJun 2, 2021BROMFENAC OPHTHALMIC SOLUTION 0.09% 1.7MLCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0413-2021Class IITerminatedJun 2, 2021Metoprolol Tartrate and Hydrochlorothiazide TabletsCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0412-2021Class IITerminatedJun 2, 2021COSOPT (Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution)CGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0411-2021Class IITerminatedJun 2, 2021Atropine Sulfate Ophthalmic SolutionCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0410-2021Class IITerminatedJun 2, 2021LIDOCAINE HCL VISC 2% 100MLCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0409-2021Class IITerminatedJun 2, 2021OFLOXACIN 0.3% 5ML OPTHCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0408-2021Class IITerminatedJun 2, 2021FENOFIBRATE CAPSULESCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0407-2021Class IITerminatedJun 2, 2021METHOCARBAMOL 500MG 500CGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0406-2021Class IITerminatedJun 2, 2021SynthroidCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0405-2021Class IITerminatedJun 2, 2021Norvir Ritonavir Tablets 100 mg 30 TabletsCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0404-2021Class IITerminatedJun 2, 2021Orilissa elagolix tablets 150 mg per tablet equivalent to 155.2 mg elagolix sodiumCGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0403-2021Class IITerminatedJun 2, 2021Creon (pancrelipase) Delayed-Release Capsules Dose By Lipase Units Lipase 36CGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0402-2021Class IITerminatedJun 2, 2021NIACIN 250MG 110CGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0401-2021Class IITerminatedJun 2, 2021THERAPEUTIC M 130CGMP Deviations: Intermittent exposure to temperature excursion during storage.Cardinal Health Inc. · D-0400-2021Class ITerminatedJun 2, 2021NP Thyroid 120 Thyroid TabletsSubpotent DrugAcella Pharmaceuticals, LLC · D-0399-2021Class ITerminatedJun 2, 2021NP Thyroid 90 Thyroid TabletsSubpotent DrugAcella Pharmaceuticals, LLC · D-0398-2021Class ITerminatedJun 2, 2021NP Thyroid 60 Thyroid TabletsSubpotent DrugAcella Pharmaceuticals, LLC · D-0397-2021Class ITerminatedJun 2, 2021NP Thyroid 30 Thyroid TabletsSubpotent DrugAcella Pharmaceuticals, LLC · D-0396-2021Class ITerminatedJun 2, 2021NP Thyroid 15 Thyroid TabletsSubpotent DrugAcella Pharmaceuticals, LLC · D-0395-2021Class IIOngoingJun 2, 2021DaytranaDefective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits.Noven Pharmaceuticals Inc · D-0394-2021Class IIOngoingJun 2, 2021DaytranaDefective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits.Noven Pharmaceuticals Inc · D-0393-2021Class IIITerminatedJun 2, 2021Olmesartan Medoxomil TabletsPresence of Foreign Tablet/CapsuleAscend Laboratories LLC · D-0392-2021Class IIITerminatedMay 26, 2021Cequa (cyclosporine ophthalmic solution) 0.09%Subpotent and Presence of Particulates .Sun Pharmaceutical Industries Inc · D-0391-2021Class IITerminatedMay 26, 2021Cefixime for Oral Suspension USP 100 mg/5mLSubpotent DrugLupin Pharmaceuticals Inc. · D-0390-2021Class IITerminatedMay 26, 2021Delflex Peritoneal Dialysis Solution with 1.5% DextroseLabeling; Label Mix-up; 4.25% DEXTROSE bag was found inside a 1.5% DEXTROSE box.Fresenius Medical Care, North America · D-0389-2021Class IITerminatedMay 26, 2021Thumbs Up 7 Blue 69KMarketed without Approved NDA/ANDA: FDA analysis results obtained the presence of sildenafil and tadalafil.Bit & Bet LLC · D-0388-2021Class IIITerminatedMay 26, 2021Dry Eye TestSubpotent DrugNomax Inc · D-0387-2021Class IIITerminatedMay 26, 2021Hydrocodone Bitartrate and Homatropine Methlybromide tabletsFailed Impurities/Degradation SpecificationsKVK-Tech, Inc. · D-0386-2021Class IIOngoingMay 26, 2021Preferred Pharmaceuticals IncCMGP Deviations: Presence of NDMA impurity detected in product and exceed the Acceptable Daily Intake Limit (ADI) of 96ng/day.Preferred Pharmaceuticals, Inc. · D-0385-2021Class IITerminatedMay 26, 2021Sterile Water for InjPresence of Particulate Matter: particulate matter identified as an insect in one vial.Pfizer Inc. · D-0384-2021Class IIOngoingMay 26, 2021Triple SupremeZen Plus 3500Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.Hyobin LLC · D-0383-2021Class IIOngoingMay 26, 2021PremierZen Black 5000Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.Hyobin LLC · D-0382-2021Class IIOngoingMay 26, 2021PremierZen Extreme 3000Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.Hyobin LLC · D-0381-2021Class IIITerminatedMay 26, 2021Asenapine Sublingual TabletsIncorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agentSigmaPharm Laboratories LLC · D-0380-2021